Krsnaa Diagnostics Ltd (KRSNAA) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Krsnaa Diagnostics Ltd demonstrated resilient performance, achieving steady growth and healthy margins despite operating in a capital-intensive segment and offering services at 40-60% lower than market rates.
- The company reported an impressive 11% year-on-year revenue growth, showcasing the self-sustaining strength of its business model even as some PPP contracts completed their initial tenure.
- Profitability significantly improved, with EBITDA growing by 18% year-on-year and PAT increasing by 22% year-on-year, reflecting enhanced structural efficiencies and operational excellence.
- The retail (direct-to-consumer) business surged by an impressive 60% quarter-on-quarter, contributing approximately 8% to first-half revenues and showing robust growth trajectory.
- The company is progressing well with the Rajasthan PPP project, India's largest diagnostic PPP, with significant operationalization planned by Q4 FY26, expected to add a substantial layer of growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.